An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

This first-in-human trial is evaluating a new experimental treatment called VCTX211 for type 1 diabetes (T1D). VCTX211 uses gene-edited cells designed to produce insulin without triggering an immune rejection response — meaning it may not require immunosuppressant drugs. **You may be eligible if...** - You have had a confirmed diagnosis of type 1 diabetes for at least 5 years - Your diabetes management has been stable for at least 3 months **You may NOT be eligible if...** - You have a history of islet cell, kidney, or pancreas transplant - You had 2 or more severe unexplained low blood sugar episodes in the past 6 months - You have a type of diabetes other than type 1 - You took immunosuppressive medications in the past 30 days or need them ongoing - You have previously received gene therapy or a gene-edited cell product Talk to your doctor to see if this trial is right for you.